循环肿瘤DNA在膀胱癌诊治中的研究进展

Research progress of circulating tumor DNA in the diagnosis and treatment of bladder cancer

膀胱癌是常见的泌尿系肿瘤,其诊断、预后评估和术后随访主要依靠膀胱镜检查和组织病理活检。循环肿瘤DNA(circulating tumor DNA,ctDNA)是一种新型无创和实时的肿瘤特异性生物标志物,与传统组织活检相比,ctDNA检测的优势在于风险小,可以进行连续检测,在协助膀胱癌的早期诊断、疗效监测、个体化治疗、预后评估及预测复发等方面均能发挥重要作用。该文对ctDNA在膀胱癌中的最新研究进展进行综述。

Bladder cancer is a common urological tumor.Its diagnosis,prognosis evaluation and postoperative follow-up mainly rely on cystoscopy and histopathological biopsy.Circulating tumor DNA(ctDNA)is a novel noninvasive and real-time tumor-specific biomarker.Compared with traditional tissue biopsy,ctDNA testing has the advantages of low risk and continuous testing.It plays an important role in the early diagnosis,therapeutic monitoring,individualized treatment,prognosis evaluation and recurrence prediction of bladder cancer.This article reviews the latest research progress of ctDNA in bladder cancer.